Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are chimeric antigen
receptor (CAR) T-cell therapies used to treat adult patients with relapsed or refractory …

We assessed stage-specific trends in primary therapy and relative survival among adult
follicular lymphoma (FL) patients diagnosed in the Netherlands between 1989–2016 (N …

Occurrence of lymphoma of the female genital tract (FGT) is extremely rare, and cohort
studies on survival rates of affected patients are sparse. The aim of this study was to …

Follicular lymphoma (FL) has a high degree of heterogeneity both clinically and molecularly.
Early treatment failure (ETF), progression or relapse within 24 months of frontline …

Follicular lymphoma (FL) is an indolent B-cell neoplasm of germinal center origin. Standard
treatment regimens consist of anti-CD20 therapy with or without chemotherapy. While high …

The introduction of anti-CD20 antibodies has improved the population-level survival of
patients with follicular lymphoma (FL)[1, 2]. Nevertheless, specific subgroups still carry a …

Background Next-generation sequencing (NGS) panels for mature B-cell neoplasms (MBNs)
are widely applied clinically but have yet to be routinely used in a manner that is suitable for …

To the Editor: Rituximab (R)-based therapies have greatly improved survival in B-cell non-
Hodgkin lymphomas (B-NHL). However, approximately 40% of patients with diffuse large B …

We assessed the impact of a prior malignancy diagnosis (PMD)–as a potential proxy for
genetic cancer susceptibility–on the development of a second primary malignancy (SPM) …

Lymphoma of the parotid gland is a rare malignant tumor, and cohort studies on the survival
rates of affected patients are sparse. This study aimed to retrospectively evaluate the …